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Anxiety disorders
nxiety is a universal response to threatening or
frightening situations.Those individuals who present with
more pronounced or persistent symptomatology,or with-
out any reasonable context,may in fact meet the diagnos-
tic criteria for an anxiety disorder.Such disorders include
generalized anxiety disorder (GAD) and panic disorder
(PD), as well as obsessive compulsive disorder (OCD),
social anxiety disorder,posttraumatic stress disorder,pho-
bias,and a number of other diagnoses.
1 Universal estimates
of prevalence are difficult to obtain,but among US resi-
dents age 18 to 54,the National Institute of Mental Health
reports that 19 million Americans (approximately 13%)
have anxiety disorders.
2In the case of GAD,for which diag-
nostic criteria were first introduced in the Diagnostic and
Statistical Manual of Mental Disorders, Third Edition
3
(DSM-III) and later also added to the International
Classification of Mental and Behavioral Disorders
4 (ICD-
10), there has been some question as to whether this is
indeed a separate disorder or part of a continuum of
another disorder,such as depression.
5 Investiga-tions sug-
gest that GAD is a distinct and common disorder,
5,6 with
lifetime prevalences reported up to 7%.
7-11 PD and the other
diagnoses appear less common.
8 Some data indicate that
anxiety disorders result in more occupational disability and
cost society more than affective disorders or schizophrenia,
and yet are vastly undertreated.
12 Estimates suggest that
both psychiatrists and primary care physicians encounter
GAD and other anxiety disorders frequently.
13-15 Making an
accurate diagnosis can be difficult—particularly in primary
care settings—because of time constraints on patient con-
tact and the fact that patients often present with physical
rather than psychological or emotional complaints.
After the diagnosis of any anxiety disorder has been estab-
lished,treatment of patients with either acute or chronic
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Anxiety disorders are common and costly psychiatric ill-
nesses. Pharmacological treatment was enhanced with the
introduction of benzodiazepines, which proved safer and
more effective than older drugs. The risk of dependence,
however, has made clinicians reluctant to use these med-
ications. In fact, few patients appear to develop signifi-
cant difficulties with these drugs, given how widely they
are used. Careful planning for discontinuation of therapy
is important. In addition, for some individuals, there
appears to be a complex and as yet unelucidated rela-
tionship between dependence on drugs or alcohol and
anxiety. The newer antidepressants offer efficacy without
abuse or dependence liability, but are expensive and have
side effects that are intolerable for some patients.
Pharmacological therapy for anxiety should be prescribed
and managed so as to minimize any existing risk, while
aiming to restore the patient to wellness in terms of symp-
toms and function.
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anxiety can be complicated by the concern that one useful
class of drugs that had shown efficacy and medical safety
in treatment settings,namely the benzodiazepines,
16-19 also
has the liability of potentially producing dependence with
chronic use.
20-25 Reclassification attempts, regulatory
actions,and dramatic anecdotal presentations of the pos-
sible problems of these medications,often in the general
media,are part of what has led to an overall decrease in
benzodiazepine use, sometimes with the substitution of
older,less safe,and less efficacious medications.
26,27 Such
prescribing decisions affect large numbers of patients of
both psychiatrists and primary care physicians,undoubt-
edly including some patients with anxiety disorders.More
recently, newer antidepressants, the selective serotonin
reuptake inhibitors (SSRIs),have shown efficacy in anxi-
ety disorders without raising the same concerns about
dependence.
28-31These medications do have their own side
effects and liabilities, which can influence the ability of
patients to adhere to therapy,however.
32 In addition,many
of these medications remain some of the most expensive
drugs on the market.The benzodiazepines,by contrast,are
largely available as generic medications and have become
very inexpensive.
Other medications have shown efficacy in anxiety disor-
ders, but these drugs also have their own drawbacks.
29
Buspirone is one of a number of compounds of the aza-
pirone group.
33,34 It is structurally unrelated to the ben-
zodiazepines,and although its mechanism of action is not
entirely known,it appears to be at least partially depen-
dent on decreasing serotonergic nerve fiber activity.
29
Buspirone shows anxiolytic activity after a number of
weeks and does not appear to have any dependence lia-
bility.Its efficacy,however,does not appear to match that
of the benzodiazepines in some studies,and it is not help-
ful in controlling acute anxiety. Older antidepressants
have been shown to have anxiolytic properties and are
sometimes used in the treatment of anxiety.
22The tricyclic
antidepressants,such as imipramine,relieve some symp-
toms in patients with generalized anxiety.The adverse
effects of these drugs are numerous,however,and their
narrow margin of safety in overdose situations dimin-
ishes their usefulness.
In an effort to expand treatment options to include reme-
dies that seem to some to be more “natural,”and therefore
implying lower risk, herbal or other alternative medi-
cine–based therapies,such as kava,are also being used.
35-37
Knowledge on the safety and efficacy of these often unreg-
ulated products is continuing to accumulate.
38,39 Kava,for
example, has been reported to show efficacy, and little
physiologic or learned tolerance was apparent in animal
models at low doses.Higher doses,however,reportedly do
result in some physiologic tolerance. In addition, kava-
kava was the focus of a consumer advisory alert from the
USA Food and Drug Administration (FDA) in 2002
because of reports from Europe and the USA of serious
hepatotoxicity.
40 It is not yet clear whether such toxicity
is a result of the chemical constituents of the herb itself or
to the presence of unexpected or unknown compounds,
which could be introduced during manufacturing or for-
mulation. It is also possible that interactions with other
substances, such as ethanol, may potentiate the toxic
potential of a compound present in the preparation.
Because of the expense of newer medications as well as
safety and efficacy concerns about some older or alter-
native medications,the possibility still remains that for
many patients with anxiety disorders,the best available
treatment will be a benzodiazepine.Understanding what
has been learned about benzodiazepine use and the
development of dependence may be helpful in ensuring
that these patients are not denied effective treatment.
41
Dependence
The reported potential of a class of prescription drugs to
result in dependence in some patients needs to be viewed
as part of an overall risk–benefit analysis in the same way
as that process is applied to nonpsychiatric medical ill-
ness. Many other authors have commented on the his-
torical biases that have been present in shaping social
views on the acceptability of treating illnesses such as
anxiety and depression with pharmacological interven-
tion.The presence of what has eloquently been called
“pharmacological Calvinism” is still a factor in the
acceptability of the appropriateness of biologically based
treatments for these disorders.
26 The context in which
medications are used includes the suffering and disabil-
ity caused by the condition being treated as well as the
overall risks of a proposed therapy for a given patient.
Definitions of substance dependence often lack consis-
tency,but they usually include a number of criteria com-
posed of issues relating to psychological dependence
and/or physical dependence.
1 In many characterizations,
there are overlaps with abuse and addiction.Table I sum-
marizes the Diagnostic and Statistical Manual of Mental
Disorders,Fourth Edition
1 (DSM-IV) criteria for depen-
dence.A central concept is the exhibition of a maladap-tive pattern of substance use leading to clinically signif-
icant impairment or distress.Accompanying features may
include tolerance, which can result in an escalation in
dose,and patients may spend inordinate amounts of time
obtaining, using, and recovering from the drug. Drug
seeking and drug use may become more important than
customary social,recreational,and occupational obliga-
tions and activities,and the patient often knows that the
use of the drug may be causing physical and/or psycho-
logical problems. Attempts to control or reduce sub-
stance use are unsuccessful,and a withdrawal syndrome
characteristic for the given substance may occur.
Although much of the focus on dependence emphasizes
what happens when the drug is discontinued,concerns
about reinforcing effects with acute administration are
also important.Euphorogenic effects,which have been
described as enhancing abuse liability,are also a compo-
nent of the discussion of psychological dependency.
Benzodiazepines
First introduced in the 1960s with the appearance of
chlordiazepoxide and diazepam, the benzodiazepines
quickly supplanted the barbiturates as the preferred
treatment of most anxiety disorders.
18,19,42 They have
shown efficacy in both acute and chronic anxiety states,
and they have a wide margin of medical safety.As a class,
they also have utility as anticonvulsants,muscle relaxants,
hypnotics,and adjuncts to anesthesia and conscious seda-
tion. Some effects, such as sedation and anterograde
amnesia,are a desirable effect in certain settings,such as
in the treatment of insomnia or in the endoscopy suite,
but are considered undesirable side effects under cir-
cumstances such as the treatment of anxiety.Tolerance
appears to develop over time to some of the sedating
properties of the benzodiazepines. Tolerance to other
effects also seems to occur,but along distinctly different
time courses,suggesting mechanistic differences.Abrupt
discontinuation can lead to insomnia and anxiety after
more than a couple of weeks of using short-acting ben-
zodiazepines to treat sleep disorders.Patients who have
been receiving daily therapy with longer-acting agents for
anxiety and other diagnoses,and whose therapy has been
suddenly halted or reduced, can experience a range of
withdrawal symptoms.
18These are usually mild and tran-
sient,and may include both psychological and physical
symptoms.Heightened anxiety,tremor,tachycardia,and
photophobia are some of the symptoms that are often
reported.In extreme cases following prolonged therapy
with high doses, seizures and delirium can occur. The
duration of therapy,dose of medication,and manner in
which therapy is discontinued are all important determi-
nants of whether a withdrawal syndrome will occur and
how severe it will be.It is important to keep in mind that
other medications that are not thought of as having
dependence liability also cause a physiologic “rebound”
or other pronounced adverse effects if stopped abruptly.
β-Adrenergic blockers are one example of such a med-
ication. These drugs are therapeutically important in
patients with hypertension and coronary artery disease,
with proven efficacy in reducing actual mortality in some
cohorts,but they can result in a withdrawal syndrome if
therapy is suddenly stopped. Signs and symptoms can
include a return of hypertension as well as tremor,pal-
pitations,and sweating,and can be as severe as the pre-
cipitation of arrhythmias and unstable angina in patients
with severe underlying coronary disease.Hence,benzo-
diazepines are not unique in their ability to cause clinical
difficulties after sudden,unstructured discontinuation.
All benzodiazepines interact with the γ-aminobutyric acid
receptor (GABAA) and produce similar physiological and
clinical effects.
43,44The anxiolytic effect appears to be medi-
ated by the alpha-2 subunit of the receptor complex.
Preferred terminology refers to these drugs as positive
modulators since they do not have any effect in the
absence of GABA.With chronic exposure,a number of
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Table I. Characteristics of the substance dependence syndrome.
“Physiological dependence” is present if either Item 1 or Item
2 is applicable. Adapted in part from reference 1.
1. Tolerance, evidenced by either or both of:
a.Increased dosage needed over time to achieve 
desired outcome
b.Diminishing effect over time despite unchanged 
dosage
2. Withdrawal, evidenced by either or both of: 
a.Withdrawal syndrome on discontinuation
b.Continued drug use to prevent or avoid withdrawal
3. Dosage larger or duration of use longer than intended
4. Inability to reduce or control drug use
5. Excessive drug-seeking behavior
6. Social, occupational, or recreational activities given up 
or impaired due to drug use
7. Continued drug use despite knowledge of adverse 
physical or psychological consequencesmolecular effects have been reported.
43-45 Downregulation
of binding sites with a reduction in the number of the
GABAA receptors is one molecular phenomenon that has
been proposed as a mechanism for tolerance. Other
changes that have been reported include changes in
mRNA,a disturbance in the linking relationship between
the benzodiazepine site and GABA,and perturbations in
the rate of turnover of subunits of the benzodiazepine
receptor.Determinations of whether these findings can be
directly and causally linked to tolerance and discontinua-
tion syndromes have been difficult because of the differ-
ences in timing of the molecular and clinical phenom-
ena.
46,47 Molecular changes seem to occur more quickly
than the development of clinical tolerance.
Although the benzodiazepines work via a common
mechanism of action,there are definite pharmacokinetic
and metabolic differences that affect the presence and
concentration of an active entity at the molecular site of
action.
48These differences determine the clinical indica-
tions for which a given benzodiazepine is used,and they
also result in differences in clinical course once an admin-
istered medication is discontinued.
49-51The most impor-
tant factors in this realm are the speed at which the par-
ent drug is cleared and the presence or absence of
pharmacologically active metabolites (Table II).As an
example,for a drug such as diazepam,the parent drug is
cleared slowly, and at least three metabolically active
compounds are generated during the course of its clear-
ance. Some of these compounds are actually separate
benzodiazepine entities available for prescription is their
own right.After one 10 mg dose of diazepam,pharma-
cologically active metabolites are detectable for at least
2 weeks. Hence, even with abrupt discontinuation of
diazepam,an intrinsic tapering process results (Figure 1).
The potency of a given benzodiazepine parent drug at
the site of activity is not a major determinant of clinical
differences,since dosages are adjusted to produce a clin-
ical effect through the same molecular mechanism.
Interestingly,other physical differences between diazepam
and some other benzodiazepines may affect its abuse
potential among some patients.Diazepam is exceedingly
lipophilic,with nearly immediate central nervous system
(CNS) penetration upon administration.
52,53The speed of
onset of sensation has been linked to abusability for other
medications,such as opiates,and may be a factor for some
patients treated with diazepam.For those involved with
use of illicit drugs, including the illegal use of benzodi-
azepines,investigators have not been able to designate any
particular benzodiazepine as preferentially abused.
Instead,many factors in a local drug use culture seem to
be important in determining the individual user’s benzo-
diazepine of choice.
26
Most information indicates that treatment with benzodi-
azepines for at least a few weeks is needed before with-
drawal is generally a serious concern,and that withdrawal
is most likely to occur when shorter-acting agents are
stopped abruptly.Taper regimens have been described to
lessen the difficulty in discontinuing benzodiazepine ther-
apy.
51,54 Most emphasize that the initial decrement in
dosage can be fairly rapid,with some authors aiming for
getting to one-fourth to one-half of the initial dosage over
the course of the first month. Others aim for a dosage
equivalent to approximately 10 mg diazepam.Tapering
from that point is slow,especially in patients with panic dis-
Pharmacological aspects
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Table II. Representative benzodiazepine derivatives in clinical use as antianxiety agents. The usual range of elimination half-life is shown in paren-
theses. *Prodrug, converted to desmethyldiazepam.
Parent drug Clinically important active metabolites
Chlordiazepoxide (5-30 h) Desmethylchlordiazepoxide
Diazepam (20-70 h) Desmethyldiazepam (36-96 h)
(minor metabolites: temazepam, oxazepam)
Prazepam* Desmethyldiazepam (36-96 h)
Clorazepate* Desmethyldiazepam (36-96 h)
Halazepam* Desmethyldiazepam (36-96 h)
Clobazam (20-30 h) Desmethylclobazam (48-72 h)
Clonazepam (18-36 h) —
Alprazolam (8-15 h) —
Oxazepam (5-15 h) —
Lorazepam (10-20 h) —
Bromazepam (20-30 h) —orders, and patients may remain at steady, low doses of
benzodiazepines for many months.
Difficulty in tapering,with more pronounced withdrawal
symptoms,does not seem to predict inability to success-
fully complete the taper.Psychological support appears
to be a critical factor in this process.
55A number of phar-
macological agents have been proposed as useful
adjuncts during the withdrawal process.
54,56These include
β-adrenergic blockers,antidepressants,and buspirone.
The majority of patients treated with chronic benzodi-
azepines are able to successfully taper off their therapy.
In a study that looked at those completing the taper,
most were still not requiring benzodiazepines 3 years
later.
54The issue of whether differences among treatment
regimens (as needed versus scheduled dosing) can result
in differing propensities for leading to discontinuation
syndromes or dependence has also been raised and con-
tinues to be investigated.
57
Research into the relationship between the benzodi-
azepines and dependence in patients with anxiety disor-
ders has failed to produce a consensus opinion regarding
causality.There seems to be wide agreement among inves-
tigators of this topic that most patients who use benzo-
diazepines do not generally misuse these medications or
become chronically dependent on them.
17,26 Hence,in dis-
cussing those who abuse benzodiazepines or cannot dis-
continue therapy,it is important to keep in mind that this
constitutes a minority of patients who are treated with
these drugs.Investigating whether certain subgroups of
patients might be at increased risk of developing signifi-
cant dependence from treatment is an extremely impor-
tant issue in the treatment of anxiety,since many of these
patients require relatively long periods of treatment.The
risk of dependence in general is felt to increase also with
the presence of some patient factors.These include—but
are not limited to—the nature of the diagnosis at the time
of treatment initiation,the level of anxiety prior to treat-
ment,the presence of personality disorders,and a current
or past history of substance abuse or dependence.
54,55,58 For
some chronically treated patients, it appears that the
development of a “withdrawal syndrome,”which would
suggest physical and psychological dependence and
results in difficulty in stopping drug treatment,may in fact
be at least in part a reemergence of the original pathol-
ogy that initially required treatment.Similar phenomena
occur following the discontinuation of antidepressants
and antipsychotics in some patients, with the ensuing
reemergence of depression and psychosis,respectively.
In addition,for some individuals,there appears to be a
reciprocating and complex relationship between anxiety
and dependence on other substances.
59-68 Individuals
dependent on other nonbenzodiazepine medications,
such as analgesics,as well as alcohol,nicotine,and illicit
drugs, are often reported to have concomitant anxiety
disorders.The extent to which independent anxiety dis-
orders and substance abuse are related has not been
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Figure I. Plasma concentrations of diazepam (blue circles) and its principal pharmacologically active metabolite, desmethyldiazepam (light-blue circles),
in a healthy volunteer who took 2.5 mg of diazepam orally twice a day for 15 days. A. Plasma levels are shown for 12 to 15 h after the initial
dose on day 1, and after the last dose on day 15. Note that there is extensive accumulation of diazepam and desmethyldiazepam, such that
levels on day 15 exceed those on day 1. B. Slow elimination of both compounds after the last dose administered on day 15.
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B Aresolved. Study of this issue has been complicated by
many factors,including the fact that drug use and with-
drawal can precipitate anxiety symptoms. It has been
postulated that some individuals may have become
dependent on substances while trying to self-medicate
anxiety or other psychiatric disorders. Alternatively,
another variable,such as a genetic factor,may promote
both conditions. Because of this possible link between
dependence as a phenotype and dependence difficulties
with multiple substances,the traditional recommenda-
tion has been to avoid the use of benzodiazepines in indi-
viduals with any history of substance abuse or depen-
dence.Such patients were felt to be at increased risk for
developing dependence on benzodiazepines.In addition,
benzodiazepines were felt to be capable of inducing a
relapse of the original substance abuse problem.Some
authors have pointed out that empirical evidence does
not fully support these generalizations,
69 and further
study is needed.
Selective serotonin reuptake inhibitors
Beginning with the introduction of fluoxetine and flu-
voxamine in the 1980s for depression,this class of med-
ications now includes some of the most widely and fre-
quently prescribed drugs in the world.They have proven
to be efficacious and safe.
29-32,70Agents also include sertra-
line,citalopram,paroxetine,and the mixed serotonin and
norepinephrine reuptake inhibitor venlafaxine.They have
been generally referred to as the SSRIs.These drugs are
now used in both pediatric and adult populations across
a wide and growing range of indications,which include a
number of anxiety disorders.The SSRIs are listed by some
as their preferred first-line treatment for many anxiety
disorders.These drugs have not to date been reported to
have a propensity to cause dependence or abuse,though
a “discontinuation syndrome”has been described.
71-76A
panel of recognized authorities on the pharmacotherapy
of anxiety and depression was near unanimous in its rat-
ing of members of the SSRI class of drugs as offering less
relative risk of dependence when compared with the ben-
zodiazepines.
77 One major drawback to their use, how-
ever,has been the lag between treatment initiation and
the onset of antianxiety activity.Hence,they are not use-
ful for treatment of acute anxiety.Because their use is not
accompanied by the worry of dependence,they may allow
more clinicians to confidently begin pharmacological
treatment for patients who suffer from chronic anxiety
disorders.Some clinicians have described a treatment par-
adigm that utilizes concomitant benzodiazepine treatment
during the time that it is anticipated to be required for
SSRIs to exert an anxiolytic effect.
Tolerability of side effects has also been a concern with
these medications.
32 Sexual dysfunction and weight gain
are frequently problems for patients taking these drugs
over the spectrum of indications. In addition, some
patients experience initial insomnia,restlessness,and agi-
tation.Precipitation of overt panic attacks have also been
reported.
78,79 For patients who take numerous medica-
tions,such as many elderly patients,some of the SSRIs
can be difficult to blend into a medication regimen
because of their ability to cause clinically important drug
interactions.
80 Although regarded as nonsedating and
thus less likely to be a hazard for accidents and falls,it
should be noted that the SSRIs have also been linked to
increased falls in the elderly.
81-84
The discontinuation syndrome that has been noted by
many authors
71-76 and investigators includes both physical
and psychological symptoms, including lethargy,
headache,and dizziness.The course is usually mild,with
spontaneous resolution within a month.The cause may
be transient serotonin dysregulation following abrupt
withdrawal of an SSRI.As with the benzodiazepines,dif-
ferences between SSRIs are seen with regard to their
propensity to cause this syndrome following cessation.
Drugs with slower clearance and pharmacologically
active metabolites,such as fluoxetine,are reported to be
less likely to cause this condition when stopped as com-
pared with a drug such as paroxetine,which is not known
to have active metabolites.
76 Norfluoxetine, the active
metabolite of fluoxetine,is detectable for weeks follow-
ing cessation of chronic fluoxetine therapy. Tapering
medication prior to stopping is suggested to minimize the
discontinuation syndrome.
Conclusion
Anxiety is an important cause of disability in the com-
munity and has been underrecognized and undertreated.
Treatment should aim for a remission of all major and
debilitating symptoms.Therapy with the benzodiazepines
has always been complicated by the worry of medication
dependence, though only a minority of those on treat-
ment appear to develop significant difficulties with
dependence or the overlapping syndromes of abuse and
addiction.Careful tapering of medication prior to stop-
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rienced in discontinuing therapy,especially when this is
combined with psychological support.Additionally,the
phenomena of a physiological rebound and/or a return
of underlying psychopathology affect patients treated
with medications for other conditions,without causing
the trepidation and stigma that are attached to benzo-
diazepine use for treatment of anxiety. More study is
needed to identify the patient factors that might be pre-
dictive of difficulty with this class of drugs.
Newer medications offer the possibility of a wider spec-
trum of efficacy without the same concerns of depen-
dence.It is hoped that the SSRIs will allow many more
clinicians to confidently treat patients with anxiety dis-
orders,without the fear of having to use drugs regarded
as having abuse potential.Expense or side effects,how-
ever,could preclude some patients from being able to use
these medications.Because the suffering with these dis-
orders is substantial, anxiety disorders should not go
untreated.Clinicians are urged to consider the issue of
the possibility of dependence in the context of overall
medical safety and efficacy. ❏
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Ansiedad y dependencia de medicamentos
Los trastornos de ansiedad son enfermedades psi-
quiátricas comunes y de alto costo económico. El
tratamiento farmacológico mejoró con la intro-
ducción de las benzodiazepinas, lo que resultó ser
más seguro y efectivo que con los fármacos más
antiguos. Sin embargo, el riesgo de dependencia
ha determinado que los clínicos sean reticentes con
el uso de estos medicamentos. Sin embargo,
teniendo en cuenta el amplio uso de este tipo de
fármacos, los problemas reales detectados a nivel
de paciente, no son significativos. Es importante un
plan cuidadoso para discontinuar el tratamiento.
Además, en algunos sujetos parece existir una com-
pleja relación aun no aclarada entre la dependen-
cia a drogas o alcohol y la ansiedad. Los antidepre-
sivos más modernos ofrecen gran eficacia sin riesgo
de abuso o dependencia, pero son caros y tienen
efectos secundarios que resultan dificiles de sopor-
tar para algunos pacientes. La terapia farmacoló-
gica para la ansiedad debe ser prescrita y manejada
con dos objetivos: minimizar cualquier riesgo exis-
tente y orientarse hacia la recuperación del bie-
nestar del paciente en términos somáticos y fun-
cionales.
Dépendance médicamenteuse et anxiété
Les troubles anxieux sont des maladies psychia-
triques fréquentes et onéreuses. Le traitement
pharmacologique a été amélioré par l’introduction
des benzodiazépines, qui se sont révélées plus sûres
et plus efficaces que les médicaments plus anciens.
Cependant, le risque de dépendance a rendu les
praticiens réticents à les utiliser. En pratique, peu
de patients semblent rencontrer de réels problèmes
avec ces médicaments, eu égard à leur très large
utilisation. Une planification soigneuse du sevrage
thérapeutique est importante. De plus, une relation
complexe et encore non élucidée entre la dépen-
dance médicamenteuse ou alcoolique et l’anxiété
semble exister chez certains sujets. Les antidépres-
seurs plus récents se caractérisent quant à eux par
une efficacité sans risque d’emploi abusif ou de
dépendance. En revanche, ils sont coûteux et pro-
voquent des effets indésirables insupportables chez
certains patients. La prescription et le suivi du trai-
tement pharmacologique de l’anxiété ont comme
double objectif de restaurer la bonne santé du
patient tant sur le plan des symptômes que de son
fonctionnement, tout en réduisant au minimum les
risques existants.REFERENCES
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